Patient and transplantation characteristics
| Characteristic . | Value . |
|---|---|
| No. enrolled | 47 |
| Median age, y (range) | 11 (2-20) |
| Sex, male/female | 25/22 |
| Diagnoses, no. of recipients | |
| ALL | |
| CR2 | 4 |
| CR3 | 12 |
| Secondary | 1 |
| AML | |
| CR2 | 7 |
| CR3 | 3 |
| PR2+ | 2 |
| Secondary | 3 |
| MDS | |
| RA | 1 |
| Secondary | 6* |
| JMML | |
| CR2 | 1 |
| CR3 | 1 |
| MLL | |
| CR3 | 1 |
| CML | |
| CP relapse after a myeloablative allogeneic transplantation | 1 |
| Hodgkin lymphoma | |
| CR3 | 3 |
| PR3 | 1* |
| Non-Hodgkin lymphoma | |
| PR3 | 1 |
| Stem cell source (HLA matching) | |
| Related donor bone marrow | 8 (2 patients, 7/8) |
| Related donor peripheral blood stem cells | 8 (all patients, 8/8) |
| Unrelated donor bone marrow | 10 (1 patient, 7/8; 1 patient, 6/8) |
| Unrelated donor peripheral blood stem cells | 9 (2 patients, 7/8; 1 patient, 6/8) |
| Unrelated donor cord blood | 12 (6 patients, 5/6; 6 patients, 4/6) |
| Qualifying toxicities | |
| Previous myeloablative allogeneic BMT | |
| TBI regimen | 16 |
| Non-TBI regimen | 7 |
| Previous myeloablative autologous BMT | |
| Non-TBI regimen | 7 |
| Significant organ toxicity | |
| Cardiac | 4 |
| Pulmonary | 2 |
| Renal | 3 |
| Liver | 1 |
| Infection | |
| Invasive fungal | 3 |
| Recipient CR3+ receiving unrelated donor BMT | |
| Primary qualifying toxicity | 2 |
| CR3+ unrelated donor with other qualifying toxicity | 18 |
| Other factors placing recipient at high risk of TRM | |
| Down syndrome | 4 |
| Combination of toxicities | 2 |
| Characteristic . | Value . |
|---|---|
| No. enrolled | 47 |
| Median age, y (range) | 11 (2-20) |
| Sex, male/female | 25/22 |
| Diagnoses, no. of recipients | |
| ALL | |
| CR2 | 4 |
| CR3 | 12 |
| Secondary | 1 |
| AML | |
| CR2 | 7 |
| CR3 | 3 |
| PR2+ | 2 |
| Secondary | 3 |
| MDS | |
| RA | 1 |
| Secondary | 6* |
| JMML | |
| CR2 | 1 |
| CR3 | 1 |
| MLL | |
| CR3 | 1 |
| CML | |
| CP relapse after a myeloablative allogeneic transplantation | 1 |
| Hodgkin lymphoma | |
| CR3 | 3 |
| PR3 | 1* |
| Non-Hodgkin lymphoma | |
| PR3 | 1 |
| Stem cell source (HLA matching) | |
| Related donor bone marrow | 8 (2 patients, 7/8) |
| Related donor peripheral blood stem cells | 8 (all patients, 8/8) |
| Unrelated donor bone marrow | 10 (1 patient, 7/8; 1 patient, 6/8) |
| Unrelated donor peripheral blood stem cells | 9 (2 patients, 7/8; 1 patient, 6/8) |
| Unrelated donor cord blood | 12 (6 patients, 5/6; 6 patients, 4/6) |
| Qualifying toxicities | |
| Previous myeloablative allogeneic BMT | |
| TBI regimen | 16 |
| Non-TBI regimen | 7 |
| Previous myeloablative autologous BMT | |
| Non-TBI regimen | 7 |
| Significant organ toxicity | |
| Cardiac | 4 |
| Pulmonary | 2 |
| Renal | 3 |
| Liver | 1 |
| Infection | |
| Invasive fungal | 3 |
| Recipient CR3+ receiving unrelated donor BMT | |
| Primary qualifying toxicity | 2 |
| CR3+ unrelated donor with other qualifying toxicity | 18 |
| Other factors placing recipient at high risk of TRM | |
| Down syndrome | 4 |
| Combination of toxicities | 2 |
One patient with Hodgkin lymphoma in PR3 also had secondary MDS.